The investigational drug daraxonrasib may offer new hope for people diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC). The latest clinical trial results support the upcoming launch of the RASolute 303 global Phase 3 study which will test daraxonrasib—alone and in combination with standard chemotherapy—in people starting treatment for metastatic PDAC.
Key Results: Promising Activity and Safety
- Daraxonrasib, taken as a daily pill, was studied in people who already had standard treatment for advanced PDAC. The drug showed encouraging results, with about one-third of patients seeing their tumors shrink (response rates of 29–35%), and the majority experiencing disease control (over 90%). Median survival ranged from 13 to nearly 16 months. These outcomes compare favorably to the roughly 7–8 months median survival typically seen with standard chemotherapy.
- In patients receiving daraxonrasib as their first treatment, early results were even more encouraging: nearly half (47%) saw their tumors shrink, and 89% had disease control. The majority are still on treatment, so more follow-up is needed to confirm long-term benefits.
- When daraxonrasib was combined with standard chemotherapy (gemcitabine and nab-paclitaxel), the results were also promising, with a higher response rate (55%) and disease control in 90% of patients.
- Across all groups, daraxonrasib was generally well-tolerated. Few patients experienced severe side effects, and most side effects were manageable. No new or unexpected safety concerns were found.
What’s Next: Phase 3 RASolute 303 Trial
Because of these encouraging results, Revolution Medicines will open a new global Phase 3 study—RASolute 303—later this year. This study will assign participants randomly to one of three groups: daraxonrasib alone, daraxonrasib with chemotherapy, or chemotherapy alone. The goal is to find out if daraxonrasib, by directly blocking RAS proteins that drive most pancreatic cancers, can help patients live longer and have better control of their disease.
Why This Matters
Metastatic pancreatic cancer is one of the hardest cancers to treat. Most patients have cancers driven by RAS mutations, which have been very difficult to target until now. Daraxonrasib is designed to block several forms of mutated RAS, and could become the first drug in its class to make a meaningful difference for people facing this aggressive disease.
If you or a loved one has been diagnosed with metastatic PDAC, ask your treatment team about whether participating in clinical trials like RASolute 303 might be appropriate, and stay tuned for ongoing research updates as new treatment options are developed.
Reference:
